UPSpace will be temporarily unavailable tonight from 19:00 to 23:00 (South African Time) due to scheduled maintenance. We apologise for any inconvenience this may cause and appreciate your understanding
 

A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma

dc.contributor.authorPazzi, Paolo
dc.contributor.authorFosgate, Geoffrey Theodore
dc.contributor.authorRixon, Anouska J.
dc.contributor.authorHanekom, Josef Derek
dc.contributor.authorKristensen, Annemarie T.
dc.contributor.authorGoddard, Amelia
dc.date.accessioned2024-02-08T07:27:52Z
dc.date.available2024-02-08T07:27:52Z
dc.date.issued2023-09
dc.descriptionSUPPORTING INFORMATION : DATA S1: Supporting Information. TABLE S1: Signalment, diagnosis, clinical, and thromboemboli details for the 3 dogs in which a macrothrombi was identified at post mortem in this prospective study evaluating thromboembolic disease. TABLE S2: Primary tumor and concurrent secondary tumor and/or comorbidity identified in dogs with microthrombi (excluding dogs with macrothrombi). TABLE S3: Hematology, biochemistry, and hemostatic variables in healthy unaffected dogs and the 3 dogs in which a macrothrombi was identified. TABLE S4: Medication administered to dogs diagnosed with carcinoma or sarcoma in the 2 weeks prior to euthanasia (excluding dogs with macrothrombi). TABLE S5: Variables with P value.en_US
dc.description.abstractBACKGROUND : Knowledge of the prevalence of thromboemboli and the associated hemostatic status in dogs with carcinoma or sarcoma is unknown and might allow earlier intervention. OBJECTIVES : Estimate prevalence of thromboemboli and their association with hemostatic changes in dogs with carcinomas or sarcomas; estimate predictive values of hemostatic variables for thromboembolic disease in tumor-bearing dogs. ANIMALS : Thirty-two dogs with sarcoma, 30 with carcinoma, 20 healthy age-controlled dogs. METHODS : Prospective cross-sectional study. A hemostasis panel (platelet concentration, thromboelastography, fibrinogen and D-dimer concentration, factor X, VII and antithrombin activity) was performed in all dogs. Tumor-bearing dogs underwent complete post mortem and histopathological evaluation. Comparisons between healthy dogs and tumor-bearing dogs with and without intracavitary hemorrhage; and tumor-bearing dogs with and without microthrombi were analyzed. RESULTS : Thromboembolic disease was identified in 32/62 (52%, 95% CI: 39%-65%) tumor-bearing dogs. Microthrombi were identified in 31/62 (50%, 95% CI: 37%-63%) dogs, 21/31 (68%, 95% CI: 49%-83%) had exclusively intra-tumoral microthrombi, 10/31 (32%, 95% CI: 17%-51%) had distant microthrombi. Macrothrombi were identified in 3 tumor-bearing dogs. Hemostatic changes potentially consistent with overt and non-overt disseminated intravascular coagulation were identified in some tumor-bearing dogs. D-dimer concentrations were significantly higher (P = .02) and platelet concentration significantly lower (P = .03) in tumor-bearing dogs with microthrombi compared to tumor-bearing dogs without microthrombi. D-dimer concentration above 500 ng/mL was 80% sensitive and 41% specific for the prediction of microthrombi presence. CONCLUSION : The high microthrombi prevalence and concomitant hemostatic dysfunction in dogs with carcinomas or sarcomas has not previously been reported, though the clinical importance is unknown. Increased D-dimer concentration might increase suspicion of microthrombi.en_US
dc.description.departmentMammal Research Instituteen_US
dc.description.departmentZoology and Entomologyen_US
dc.description.librarianhj2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipAgricultural Sector Education Training Authority and the University of Pretoria.en_US
dc.description.urihttp://wileyonlinelibrary.com/journal/jvimen_US
dc.identifier.citationPazzi, P., Fosgate, G.T., Rixon, A., Hanekom, J., Kristensen, A.T. & Goddard, A.. A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma. Journal of Veterinary Internal Medicine 2023; 37(5): 1848‐1863. doi: 10.1111/jvim.16828.en_US
dc.identifier.issn0891-6640 (print)
dc.identifier.issn1939-1676 (online)
dc.identifier.other10.1111/jvim.16828
dc.identifier.urihttp://hdl.handle.net/2263/94376
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rights© 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License.en_US
dc.subjectCanceren_US
dc.subjectHemangiosarcomaen_US
dc.subjectHemostasisen_US
dc.subjectMacrothrombien_US
dc.subjectThromboelastographyen_US
dc.subjectDogs (Canis familiaris)en_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titleA prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcomaen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 5 of 7
Loading...
Thumbnail Image
Name:
Pazzi_Prospective_2023.pdf
Size:
1.31 MB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Pazzi_ProspectiveDataS1_2023.pdf
Size:
86.21 KB
Format:
Adobe Portable Document Format
Description:
Data S1
Loading...
Thumbnail Image
Name:
Pazzi_ProspectiveTabS1_2023.pdf
Size:
119.73 KB
Format:
Adobe Portable Document Format
Description:
Table S1
Loading...
Thumbnail Image
Name:
Pazzi_ProspectiveTabS2_2023.pdf
Size:
129.79 KB
Format:
Adobe Portable Document Format
Description:
Table S2
Loading...
Thumbnail Image
Name:
Pazzi_ProspectiveTabS3_2023.pdf
Size:
115.95 KB
Format:
Adobe Portable Document Format
Description:
Table S3

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: